Concepedia

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

Luis Paz‐Ares, Hossein Borghaei, Stephen V. Liu, Solange Peters, Roy S. Herbst, Katarzyna Stencel, Margarita Majem, Mehmet Alı Nahıt Şendur, Grzegorz Czyżewicz, Ki Hyeong Lee,

The Lancet · 2025 · 64 citations · 22 references

DOI

Concepts

References

22

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · New England Journal of Medicine · 2018 · 3.5K citations · Full text

, , +17

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

, , +14

A Confidence Interval for the Median Survival Time

Ron Brookmeyer, John Crowley · Biometrics · 1982 · 908 citations

, , +16

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Stephen V. Liu, Martin Reck, Aaron S. Mansfield et al. · Journal of Clinical Oncology · 2021 · 824 citations · Full text

, , +16

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

, , +14